tick2trade
Natco Pharma Announces Fund Raise Details
By Tick2Trade
2 min read

Natco Pharma Announces Fund Raise Details

Natco Pharma announces a fund raise with details on instrument, size, and purpose disclosed.

Natco Pharma Fund Raise Announcement

Natco Pharma has announced a fund raise. Details regarding the instrument, size, price, and purpose of the fund raise have been disclosed by the company.

Company Background

Natco Pharma is a Hyderabad-based pharmaceutical company engaged in the development, manufacturing, and distribution of generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products. The company focuses on oncology and limited competition molecules in the US market. Its manufacturing facilities have approvals from regulatory authorities including the US FDA, Brazil ANVISA, Health Canada, and WHO.

Recent Regulatory Update

The company recently received the Establishment Inspection Report (EIR) from the US FDA for its Finished Dosage Formulations (FDF) unit in Visakhapatnam. The inspection, conducted in August 2026, concluded with four observations classified as Voluntary Action Indicated (VAI), which means issues were noted but do not require immediate regulatory action.

Financial Snapshot

For Q2 FY27, Natco Pharma reported consolidated total revenue of ₹1019.4 crore and a net profit of ₹202.6 crore. The operating profit was ₹257.9 crore with an operating margin of 26.66%. Earnings per share (EPS) stood at ₹11.31 for the quarter.

The company’s financial performance in recent quarters shows some variability, with Q1 FY27 net profit at ₹206.5 crore and Q4 FY26 net profit at ₹269 crore.

Summary

Natco Pharma’s fund raise details have been announced alongside ongoing regulatory and operational updates. The company continues to operate with approvals from multiple global regulatory authorities and maintains a focus on oncology and specialty pharmaceuticals.


This article is for information only and is not investment advice. Tick2Trade is not recommending buying or selling any security. Figures are from the company's exchange filing and market data at the time of writing.

Related Articles

All Topics